Chinese (Simplified)
English
German
Korean
Spanish
Sign up for an account to enjoy easy online shopping and instant order tracking.
An experiment works perfectly for months. Then, with no change to the protocol, the results suddenly stop making sense. The cells look fine. The reagents are fresh. The technique has not changed.
More often than researchers realize, the antibody is the variable that shifted. A new vial from a new lot can behave differently from the one before it, even when both are labeled identically.
This is lot to lot variability, and it is one of the most common, least visible causes of failed reproducibility in life science research. Studies estimate that irreproducible research costs roughly 28 billion dollars a year in the United States alone, with biological reagents named as a leading contributor.
This guide explains what lot to lot variability is, why it happens, how to detect it, and what practical steps protect your data from it.
Lot to lot variability, sometimes called batch variability, refers to differences in performance between separate manufacturing batches of the same antibody product.
Two vials might carry the same catalog number, the same name, and the same listed concentration. Yet one may bind more strongly, produce a cleaner signal, or show different background than the other.
This is not a labeling error. It is a structural property of how certain antibodies are made, particularly polyclonal antibodies, where no two batches are ever truly identical.
Lot to lot variability is rarely caused by one single factor. It usually comes from a combination of biological, manufacturing, and handling differences that accumulate between batches.
| Cause | Why It Happens | Most Affected |
| New host immunization | A new animal mounts a slightly different immune response each time | Polyclonal antibodies |
| Hybridoma drift | Cell lines can mutate or lose productivity over many passages | Traditional monoclonal antibodies |
| Purification process changes | Shifts in affinity chromatography conditions alter antibody yield and purity | Both polyclonal and monoclonal |
| Raw material quality | Variability in serum, media, or chromatography resin between batches | Manufacturing dependent products |
| Conjugation chemistry variation | Inconsistent labeling ratios between fluorophore or enzyme batches | Conjugated antibodies |
| Storage and handling differences | Shipping conditions and time in storage before use | Any antibody format |
Polyclonal antibodies carry the highest risk, since each new lot comes from a fresh immunization of a host animal. No two immune responses are exactly alike, even in the same animal immunized twice.
Not all antibody formats are equally vulnerable to lot to lot variability. Understanding the difference helps you choose the right format for long term or comparative studies.
| Antibody Format | Lot to Lot Risk | Why |
| Polyclonal | High | New animal immunization for every batch |
| Traditional monoclonal | Low to moderate | Same hybridoma clone, but cell line drift is possible |
| Recombinant monoclonal | Very low | Defined gene sequence expressed in a stable cell line |
Polyclonal antibodies are collected from the serum of an immunized animal, then affinity purified. Every new lot requires either a new immunization or a new bleed from the same animal, and the resulting antibody mixture is never identical twice.
Monoclonal antibodies come from a single hybridoma cell line, which should, in theory, produce identical antibody every time. In practice, hybridoma cell lines can drift genetically over many passages, occasionally reducing yield, affinity, or specificity.
Recombinant monoclonal antibodies are produced from a cloned, sequenced gene expressed in a stable, controlled cell line. Because the exact molecular sequence is known and fixed, lot to lot variability is dramatically reduced, often to a level researchers can treat as negligible.
The consequences of unnoticed batch variability are rarely dramatic. They are usually quiet, gradual, and easy to misattribute to something else.
• Standard curves shift between ELISA kit lots, changing calculated sample concentrations without an obvious cause
• Western blot band intensity changes between experiments, leading to confusing fold change calculations
• Flow cytometry staining intensity drifts, affecting gating decisions across longitudinal studies
• Published results become difficult or impossible for other labs to replicate using a newer lot of the same antibody
In long term clinical or biomarker studies, this problem compounds. One published case tracked a major shift in plasma biomarker readings after switching ELISA kit lots mid study, requiring a custom computational correction just to make the data usable.
Before fully switching to a new lot, run it alongside your current lot on the same samples, under identical conditions. Compare signal intensity, background, and specificity directly.
Keep a stable reference sample, such as a known positive control, and test every new lot against it. Significant drift in signal from this reference is an early warning sign.
For ELISA and other quantitative assays, compare the new lot's standard curve directly against your existing curve. A shift in slope or midpoint indicates the new lot is behaving differently.
Reputable suppliers test lot to lot consistency as part of quality control and may share this data on request, particularly for monoclonal and recombinant products.
• Choose recombinant monoclonal antibodies whenever long term consistency matters more than cost
• For critical, multi year studies, purchase enough vials from a single lot to cover the full project timeline
• Store antibodies properly, since temperature and light exposure can introduce apparent lot differences that are really handling differences
• Re titrate any antibody when switching to a new lot, rather than assuming the old dilution still applies
• Keep detailed records of lot numbers used in every experiment, so any future inconsistency can be traced back
• Run consistent positive and negative controls in every experiment, regardless of how confident you are in lot stability
If your results suddenly stop matching previous data, do not assume your biology has changed before ruling out the antibody.
• Check whether you are using a new lot number compared to previous successful experiments
• Run the old and new lots side by side on the same sample, if any of the previous lot remains
• Contact the supplier, many will replace or credit a lot that fails to perform as expected
• Document the issue clearly, including lot numbers, so your lab has a record for future reference
Reporting inconsistent lots back to suppliers also helps improve quality control for the wider research community, since most companies rely on user feedback to catch manufacturing drift early.
What is lot to lot variability in antibodies
Differences in performance between separate manufacturing batches of the same antibody.
Which antibody type has the most lot to lot variability
Polyclonal antibodies, since each lot comes from a new immunization.
Do recombinant monoclonal antibodies have lot to lot variability
Very little, since they come from a fixed, sequenced gene in a stable cell line.
How can I detect a bad antibody lot
Run the new lot side by side with a known good lot on the same sample.
Why did my ELISA standard curve shift after a kit change
A new kit lot likely caused the shift, a known cause of standard curve drift.
Should I buy multiple vials from the same lot
Yes, for long term studies, this avoids switching lots mid project.
Does storage affect lot to lot consistency
Yes, poor storage can mimic or worsen apparent lot differences.
Free shipping on orders $999+
Advenit post multos Scudilo Scutariorum tribunus velament
We accept credit cards, PayPal, and bank wires
Responsive and knowledgable customer service via email, text or phone
Notification
